ArticlePharmacoEconomics - open2021

Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer Perspective.

Nan Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.